Holen Sie sich die Stockscreener-App
6.795
2.03%
0.135
Handel nachbörslich:
6.95
0.155
+2.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BHC?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$6.66
Offen:
$6.64
24-Stunden-Volumen:
2.17M
Relative Volume:
0.92
Marktkapitalisierung:
$1.88B
Einnahmen:
$9.47B
Nettoeinkommen (Verlust:
$-178.00M
KGV:
-14.16
EPS:
-0.48
Netto-Cashflow:
$1.01B
1W Leistung:
+9.60%
1M Leistung:
+50.00%
6M Leistung:
-15.69%
1J Leistung:
-4.16%
1-Tages-Spanne:
$6.59
$6.975
1-Wochen-Bereich:
$6.20
$6.975
52-Wochen-Spanne:
$3.96
$9.85
Bausch Health Companies Inc Stock (BHC) Company Profile
Firmenname
Bausch Health Companies Inc
Sektor
Telefon
514-744-6792
Adresse
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Vergleichen Sie BHC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.795 | 1.88B | 9.47B | -178.00M | 1.01B | -0.48 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.36 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.65 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2024-07-10 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-20 | Hochstufung | Jefferies | Hold → Buy |
| 2023-06-16 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2022-07-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-07-29 | Herabstufung | Truist | Buy → Hold |
| 2022-07-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-06-13 | Fortgesetzt | JP Morgan | Overweight |
| 2021-03-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-02-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-01-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-09-17 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-24 | Eingeleitet | Citigroup | Buy |
| 2020-04-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-01-22 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2019-12-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-02 | Eingeleitet | Goldman | Neutral |
| 2019-10-25 | Eingeleitet | Cowen | Outperform |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-15 | Hochstufung | TD Securities | Hold → Buy |
| 2019-07-19 | Eingeleitet | Wolfe Research | Outperform |
| 2019-06-11 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-01-02 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-13 | Hochstufung | Piper Jaffray | Underweight → Neutral |
Alle ansehen
Bausch Health Companies Inc Aktie (BHC) Neueste Nachrichten
Bausch + Lomb Brief: Prices Upsized Senior Secured Notes Offering - MarketScreener
GMS Posts Upbeat Earnings, Joins Coinbase Global, Genworth Financial, Sandisk And Other Big Stocks Moving Higher On Wednesday - Benzinga
Bausch Health ticks higher following large director stock purchase - MSN
John Paulson buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference - The Globe and Mail
Director buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health: Repricing Potential Driven By Deleveraging (NYSE:BHC) - Seeking Alpha
Bausch Health Companies Inc. (TSE:BHC) Director John Paulson Acquires 754,134 Shares - MarketBeat
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds - Yahoo Finance
LOOK: These 10 Stocks Just Stole The Show - Insider Monkey
Bausch Health (BHC) Rises After Director's $15M Share Purchase - GuruFocus
Bausch Health Companies Stock Price, Quotes and Forecasts | NYSE:BHC - Benzinga
Hedge Fund and Insider Trading News: Philippe Laffont, Warren Buffett, Bill Ackman, Farallon Capital, Bausch Health Companies Inc (BHC), MicroStrategy Inc (MSTR), and More - Insider Monkey
Rising Demand in Traveler's Diarrhea MarketTop Developments, - openPR.com
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets - The Globe and Mail
Benzodiazepine Drugs Market Trends, Growth Forecast, and Top - openPR.com
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch + Lomb Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Bausch + Lomb Brief: Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Huntington's Disease Market Grows with Increased Genetic - openPR.com
Reconstructive Surgery Market Trends, Size & Growth Forecast - openPR.com
The most oversold and overbought stocks on the TSX - The Globe and Mail
Two Sigma Investments LP Boosts Holdings in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Why Is Bausch (BHC) Down 13% Since Last Earnings Report? - Yahoo Finance
Intraocular Lens Market Is Booming So Rapidly 2025-2032 -Bausch - openPR.com
With 51% institutional ownership, Bausch Health Companies Inc. (NYSE:BHC) is a favorite amongst the big guns - Yahoo Finance
Choroidal Neovascularization Market: Insights Into Retinal - openPR.com
Verteporfin Market Projected to Witness Increased UtilizationNovartis, Valeant Pharmaceuticals - openPR.com
Actinic Keratosis Market Poised Boom | Almirall, S.A, Bausch - openPR.com
Bausch + Lomb, Organon, Globalstar, Telephone and Data Systems, and nLIGHT Shares Skyrocket, What You Need To Know - Yahoo Finance
Bausch Health’s $7.9 Billion Refinancing Transaction - Global Legal Chronicle
Zacks Research Has Bearish Forecast for BHC Q2 Earnings - Defense World
Research Analysts Offer Predictions for TSE:BHC Q2 Earnings - Defense World
Equities Analysts Set Expectations for BHC Q3 Earnings - Defense World
Colonoscopy Bowel Preparation Drugs Market Detailed Analysis - openPR.com
Facial Injectable Market Forecasts Report 2025-2030, - GlobeNewswire
Bausch Health Companies IncEnters Agreements With Icahn, Paulson, Kavanagh GroupsSEC Filing - marketscreener.com
Bausch Health and Bausch + Lomb Brief: Cos Have Cited Amendment to Definitive Proxy Statement Relating to 2025 Annual Meeting of Shareholders On May 21, 2025 - marketscreener.com
Bausch + Lomb’s New Board Agreements Announced - TipRanks
Bausch Health Signs New Board Agreements - TipRanks
Bausch Health Companies Inc. (NYSE:BHC) Receives Average Rating of “Reduce” from Analysts - Defense World
Bausch Health Companies (TSE:BHC) Stock Price Up 1.4% – Time to Buy? - Defense World
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com | FinancialContent - FinancialContent
Balyasny Asset Management L.P. Invests $97,000 in Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Global Cataract Surgery Devices Market to grow at a CAGR of 5.50% - openPR.com
Bausch Health Companies Inc. (NYSE:BHC) Stake Lessened by Stifel Financial Corp - Defense World
Bausch, Mylan Settle Patent Suit Over Generic IBS Drugs - Law360
Bausch Health’s CFO Steps In as Interim CAO - TipRanks
India Ophthalmic Devices Market Forecast Report 2025-2033, - GlobeNewswire
Genital Herpes Treatment Market reached US$ 1,143.19 million - openPR.com
Finanzdaten der Bausch Health Companies Inc-Aktie (BHC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bausch Health Companies Inc-Aktie (BHC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Paulson John | Director |
Jun 12 '25 |
Buy |
5.47 |
1,005,376 |
5,499,407 |
29,227,643 |
| Paulson John | Director |
Jun 11 '25 |
Buy |
5.24 |
1,029,098 |
5,392,474 |
28,222,267 |
| Paulson John | Director |
Jun 10 '25 |
Buy |
5.05 |
754,134 |
3,808,377 |
27,193,169 |
| Carson Seana | EVP, General Counsel |
Dec 02 '24 |
Sale |
8.35 |
440 |
3,674 |
433,066 |
1.09%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):